Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bristol Myers Squibb (BMY)

Bristol Myers Squibb raises 2026 outlook after Q2 revenue rises 6% to $13.0 billion

Positive Impact 4 of 5 earnings Written later

Bristol Myers Squibb reported second-quarter 2026 revenue of $13.0 billion, up 6% from a year earlier, and GAAP earnings of $1.62 per share, up from $0.64. The company raised its full-year 2026 revenue guidance to approximately $49.0 billion to $50.0 billion from $46.0 billion to $47.5 billion, and its non-GAAP EPS range to $6.75 to $7.00 from $6.05 to $6.35, which matters to shareholders because it signals higher expected profit for the year.

Key points

  • Q2 revenue was $12,973 million, up 6% (5% excluding foreign exchange); Growth Portfolio revenue rose 15% to $7.6 billion while Legacy Portfolio revenue fell 4% to $5.4 billion.
  • GAAP EPS was $1.62 versus $0.64 a year earlier; non-GAAP EPS was $2.04 versus $1.46.
  • 2026 non-GAAP revenue guidance was raised to approximately $49.0 billion to $50.0 billion; non-GAAP EPS guidance was raised to $6.75 to $7.00.
  • Worldwide Eliquis revenue growth guidance for 2026 was raised to 20% to 25%, from 10% to 15%.

The filing

CompanyBristol Myers Squibb (BMY)
Form8-K, current report
Filed with the SECJul 30, 2026, 7:05 AM ET
Accession number0000014272-26-000018

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.